Loading...
XASX
AT1
Market cap11mUSD
Jul 10, Last price  
0.02AUD
1D
-5.56%
1Q
-39.29%
IPO
-96.73%
Name

Atomo Diagnostics Ltd

Chart & Performance

D1W1MN
XASX:AT1 chart
P/E
P/S
4.05
EPS
Div Yield, %
Shrs. gr., 5y
2.90%
Rev. gr., 5y
-6.72%
Revenues
4m
-7.20%
294,933287,250539,7365,368,6986,715,65912,336,1112,543,7164,086,5353,792,359
Net income
-5m
L-27.41%
-5,148,490-4,900,173-5,055,112-9,218,105-6,021,215-5,706,854-9,957,632-6,847,803-4,970,934
CFO
-2m
L-58.20%
-5,255,268-5,560,317-1,838,487-6,261,928-4,225,251-2,806,642-5,847,671-4,686,104-1,958,817

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.
IPO date
Apr 16, 2020
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT